492 related articles for article (PubMed ID: 26590657)
21. The role of cerebellar abnormalities in neuromyelitis optica--a comparison with multiple sclerosis and healthy controls.
Weier K; Eshaghi A; Magon S; Andelova M; Radue EW; Kappos L; Azimi AR; Sahraian MA; Sprenger T
Mult Scler; 2015 May; 21(6):757-66. PubMed ID: 25480863
[TBL] [Abstract][Full Text] [Related]
22. Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
Hua T; Fan H; Duan Y; Tian D; Chen Z; Xu X; Bai Y; Li Y; Zhang N; Sun J; Li H; Li Y; Li Y; Zeng C; Han X; Zhou F; Huang M; Xu S; Jin Y; Li H; Zhuo Z; Zhang X; Liu Y
J Neurol; 2024 Jun; 271(6):3595-3609. PubMed ID: 38558149
[TBL] [Abstract][Full Text] [Related]
23. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
Juryńczyk M; Tackley G; Kong Y; Geraldes R; Matthews L; Woodhall M; Waters P; Kuker W; Craner M; Weir A; DeLuca GC; Kremer S; Leite MI; Vincent A; Jacob A; de Sèze J; Palace J
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):132-136. PubMed ID: 27951522
[TBL] [Abstract][Full Text] [Related]
24. Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.
Long Y; Chen M; Zhang B; Gao C; Zheng Y; Xie L; Gao Q; Yin J
J Neuroimmunol; 2014 Apr; 269(1-2):62-7. PubMed ID: 24582827
[TBL] [Abstract][Full Text] [Related]
25. Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets.
Ip PP; Chung CY; Chang CC; Lee YF; Wang HM; Lian IB; Fann CS; Yang CC; Liao F
J Neuroimmunol; 2018 May; 318():45-52. PubMed ID: 29455925
[TBL] [Abstract][Full Text] [Related]
26. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
[TBL] [Abstract][Full Text] [Related]
27. Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Masuda H; Mori M; Hirano S; Uzawa A; Uchida T; Muto M; Ohtani R; Aoki R; Kuwabara S
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):32-40. PubMed ID: 34362853
[TBL] [Abstract][Full Text] [Related]
28. Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease.
Jurynczyk M; Probert F; Yeo T; Tackley G; Claridge TDW; Cavey A; Woodhall MR; Arora S; Winkler T; Schiffer E; Vincent A; DeLuca G; Sibson NR; Isabel Leite M; Waters P; Anthony DC; Palace J
Acta Neuropathol Commun; 2017 Dec; 5(1):95. PubMed ID: 29208041
[TBL] [Abstract][Full Text] [Related]
29. High resolution retinal scanning reveals regional structural differences between MS and NMOSD optic neuritis regardless of antibody status.
Bertsch-Gout M; Loeb R; Finch AK; Javed A; Bernard J
J Neurol Sci; 2018 Jan; 384():61-66. PubMed ID: 29249380
[TBL] [Abstract][Full Text] [Related]
30. Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
Tanaka M; Tanaka K
J Neuroimmunol; 2016 Sep; 298():16-8. PubMed ID: 27609270
[TBL] [Abstract][Full Text] [Related]
31. Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients.
Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Antunes Barreira A; Armas E; Chiganer E; de Aquino Cruz C; Di Pace JL; Hryb JP; Lavigne Moreira C; Lessa C; Molina O; Perassolo M; Soto A; Caride A
Mult Scler Relat Disord; 2018 Jan; 19():73-78. PubMed ID: 29156226
[TBL] [Abstract][Full Text] [Related]
32. Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD.
Cortese R; Magnollay L; Tur C; Abdel-Aziz K; Jacob A; De Angelis F; Yiannakas MC; Prados F; Ourselin S; Yousry TA; Barkhof F; Ciccarelli O
Neurology; 2018 Apr; 90(14):e1183-e1190. PubMed ID: 29514948
[TBL] [Abstract][Full Text] [Related]
33. Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis.
Pudlac A; Burgetova A; Dusek P; Nytrova P; Vaneckova M; Horakova D; Krasensky J; Lambert L
Biomed Res Int; 2020; 2020():6492786. PubMed ID: 32509866
[TBL] [Abstract][Full Text] [Related]
34. Serum amyloid A level is increased in neuromyelitis optica and atypical multiple sclerosis with smaller T2 lesion volume in brain MRI.
Yokote H; Yagi Y; Watanabe Y; Amino T; Kamata T; Mizusawa H
J Neuroimmunol; 2013 Jun; 259(1-2):92-5. PubMed ID: 23566403
[TBL] [Abstract][Full Text] [Related]
35. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis.
Schneider E; Zimmermann H; Oberwahrenbrock T; Kaufhold F; Kadas EM; Petzold A; Bilger F; Borisow N; Jarius S; Wildemann B; Ruprecht K; Brandt AU; Paul F
PLoS One; 2013; 8(6):e66151. PubMed ID: 23805202
[TBL] [Abstract][Full Text] [Related]
36. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
[TBL] [Abstract][Full Text] [Related]
37. Personalized estimates of morphometric similarity in multiple sclerosis and neuromyelitis optica spectrum disorders.
Sun J; Zhao W; Xie Y; Zhou F; Wu L; Li Y; Li H; Li Y; Zeng C; Han X; Liu Y; Zhang N
Neuroimage Clin; 2023; 39():103454. PubMed ID: 37343344
[TBL] [Abstract][Full Text] [Related]
38. Clinical Features of Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
Chen H; Liu SM; Zhang XX; Liu YO; Li SZ; Liu Z; Dong HQ
Chin Med J (Engl); 2016 Sep; 129(17):2079-84. PubMed ID: 27569235
[TBL] [Abstract][Full Text] [Related]
39. Disrupted structural network of inferomedial temporal regions in relapsing-remitting multiple sclerosis compared with neuromyelitis optica spectrum disorder.
Cho EB; Kim D; Jeong B; Shin JH; Chung YH; Kim ST; Kim BJ; Han CE; Min JH
Sci Rep; 2022 Mar; 12(1):5152. PubMed ID: 35338192
[TBL] [Abstract][Full Text] [Related]
40. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder.
Hakobyan S; Luppe S; Evans DR; Harding K; Loveless S; Robertson NP; Morgan BP
Mult Scler; 2017 Jun; 23(7):946-955. PubMed ID: 27613120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
